Research progress of ophthalmic preparations of immunosuppressants

References

• Abdelbary G, El-Gendy N. (2008). Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech 9:1–17.
   PubMed Web of Science ®Google Scholar
• Abdulreda MH, C, Martin A, Gans, et al. (2014). Prolonged Survival of Pancreatic Islet Allografts in the Immune Privileged Anterior Chamber of the Eye. San Francisco, CA: ADA 74th Scientific Sessions.
   Google Scholar
• Agarwal P, Scherer D, Günther B, et al. (2018). Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs. Int J Pharm 538:119–29.
   PubMedGoogle Scholar
• Aksungur P, Demirbilek M, Denkbaş EB, et al. (2012). Comparative evaluation of cyclosporine A/HPβCD-incorporated PLGA nanoparticles for development of effective ocular preparations. J Microencapsul 29:605–13.
   PubMed Web of Science ®Google Scholar
• Alvarez-Trabado J, López-García A, Martín-Pastor M, et al. (2018). Sorbitan ester nanoparticles (SENS) as a novel topical ocular drug delivery system: Design, optimization, and in vitro/ex vivo evaluation. Int J Pharm 546:20–30.
   PubMedGoogle Scholar
• Ammar HO, Ghorab M, El-Nahhas SA, et al. (2011). Proniosomes as a carrier system for transdermal delivery of tenoxicam. Int J Pharm 405:142–52.
   PubMed Web of Science ®Google Scholar
• Apel A, Oh C, Chiu R, et al. (1995). A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy. Curr Eye Res 14:659–67.
   PubMed Web of Science ®Google Scholar
• Aydemir O, Celebi S, Yilmaz T, et al. (2004). Protective effects of vitamin E forms (alpha-tocopherol, gamma-tocopherol and d-alpha-tocopherol polyethylene glycol 1000 succinate) on retinal edema during ischemia-reperfusion injury in the guinea pig retina. Int Ophthalmol 25:283–9.
   PubMedGoogle Scholar
• Badr MY, Abdulrahman NS, Schatzlein AG, et al. (2021). A polymeric aqueous tacrolimus formulation for topical ocular delivery. Int J Pharm 599:120364.
   PubMedGoogle Scholar
• Baspinar Y, Bertelmann E, Pleyer U, et al. (2008). Corneal permeation studies of everolimus microemulsion. J Ocul Pharmacol Ther 24:399–402.
   PubMed Web of Science ®Google Scholar
• Bauer AC, Franco RF, Manfro RC. (2020). Immunosuppression in kidney transplantation: state of the art and current protocols. Curr Pharm Des 26:3440–50.
   PubMed Web of Science ®Google Scholar
• Benjamin D, Colombi M, Moroni C, et al. (2011). Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 10:868–80.
   PubMed Web of Science ®Google Scholar
• Bennett WM, Demattos A, Meyer MM, et al. (1996). Chronic cyclosporine nephropathy in renal transplantation. Transplant Proc 28:2100–3.
   PubMed Web of Science ®Google Scholar
• Blair J, Barry R, Moore DJ, et al. (2017). A comprehensive review of mTOR-inhibiting pharmacotherapy for the treatment of non-infectious uveitis. Curr Pharm Des 23:3005–14.
   PubMed Web of Science ®Google Scholar
• Burkholder BM, Jabs DA. (2021). Uveitis for the non-ophthalmologist. BMJ 372:m4979.
   PubMedGoogle Scholar
• Chen X, Wu J, Lin X, et al. (2022). Tacrolimus loaded cationic liposomes for dry eye treatment. Front Pharmacol 13:838168.
   PubMed Web of Science ®Google Scholar
• Cholkar K, Gunda S, Earla R, et al. (2015). Nanomicellar topical aqueous drop formulation of rapamycin for back-of-the-eye delivery. AAPS PharmSciTech 16:610–22.
   PubMed Web of Science ®Google Scholar
• Contreras-Ruiz L, De La Fuente M, Párraga JE, et al. (2011). Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. Mol Vis 17:279–90.
   PubMed Web of Science ®Google Scholar
• Cotovio P, Neves M, Santos L, et al. (2012). Conversion to everolimus in kidney transplant recipients: to believe or not believe? Transplant Proc 44:2966–70.
   PubMed Web of Science ®Google Scholar
• Coursey TG, Henriksson JT, Marcano DC, et al. (2015). Dexamethasone nanowafer as an effective therapy for dry eye disease. J Control Release 213:168–74.
   PubMed Web of Science ®Google Scholar
• Crean AM. (2009). The physicochemical basis of pharmaceuticals. USA: Oxford University Press. 156–92.
   Google Scholar
• Crowe A, Bruelisauer A, Duerr L, et al. (1999). Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 27:627–32.
   PubMed Web of Science ®Google Scholar
• Dai Y, Zhou R, Liu L, et al. (2013). Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): in vitro characterization and improved corneal permeation. Int J Nanomedicine 8:1921–33.
   PubMed Web of Science ®Google Scholar
• Danovitch GM. (2005). Immunosuppressive medications and protocols for kidney transplantation. Handbook of kidney transplantation 72–134.
   Google Scholar
• Daull P, Feraille L, Barabino S, et al. (2016). Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye. Exp Eye Res 153:159–64.
   PubMed Web of Science ®Google Scholar
• Daull P, Lallemand F, Garrigue JS. (2014). Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol 66:531–41.
   PubMed Web of Science ®Google Scholar
• Davidson J, A, Wilkinson J, Dantal, et al. (2003).New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 75:SS3–24.
   PubMed Web of Science ®Google Scholar
• De Majumdar S, Subinya M, Korward J, et al. (2017). A low concentration of tacrolimus/semifluorinated alkane (SFA) eyedrop suppresses intraocular inflammation in experimental models of uveitis. Curr Mol Med 17:211–20.
   PubMed Web of Science ®Google Scholar
• Di Tommaso C, Bourges JL, Valamanesh F, et al. (2012). Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies. Eur J Pharm Biopharm 81:257–64.
   PubMed Web of Science ®Google Scholar
• Di Tommaso C, Torriglia A, Furrer P, et al. (2011). Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly (ethylene glycol)-hexylsubstituted poly (lactide) micelle carriers. Int J Pharm 416:515–24.
   PubMed Web of Science ®Google Scholar
• Eldesouky LM, El-Moslemany RM, Ramadan AA, et al. (2021). Cyclosporine lipid nanocapsules as thermoresponsive gel for dry eye management: Promising corneal mucoadhesion, biodistribution and preclinical efficacy in rabbits. Pharmaceutics 13:360.
   PubMed Web of Science ®Google Scholar
• Elsaid N, Jackson TL, Gunic M, et al. (2012). Positively charged amphiphilic chitosan derivative for the transscleral delivery of rapamycin. Invest Ophthalmol Vis Sci 53:8105–11.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. (2015). Ikervis assessment report. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis [last accessed 12 Dec 2020].
   Google Scholar
• European Medicines Agency. (2017). Cyclodextrins used as excipients. Available at: https://www.ema.europa.eu/en/cyclodextrins [last accessed 17 Dec 2020].
   Google Scholar
• Fan Y, Zheng X, Ali Y, et al. (2019). Local release of rapamycin by microparticles delays islet rejection within the anterior chamber of the eye. Sci Rep 9:3918.
   PubMed Web of Science ®Google Scholar
• García-Otero X, Díaz-Tomé V, Varela-Fernández R, et al. (2021). Development and characterization of a tacrolimus/hydroxypropyl-β-cyclodextrin eye drop. Pharmaceutics 13:149.
   PubMed Web of Science ®Google Scholar
• Giannavola C, Bucolo C, Maltese A, et al. (2003). Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res 20:584–90.
   PubMed Web of Science ®Google Scholar
• Grimaudo MA, Pescina S, Padula C, et al. (2018). Poloxamer 407/TPGS mixed micelles as promising carriers for cyclosporine ocular delivery. Mol Pharm 15:571–84.
   PubMed Web of Science ®Google Scholar
• Guan P, Lu Y, Qi J, et al. (2011). Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomed 6:965–74.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cordier JF, Lhote F, et al. (1997). A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40:2187–98.
   PubMed Web of Science ®Google Scholar
• Han Y, Jiang L, Shi H, et al. (2022). Effectiveness of an ocular adhesive polyhedral oligomeric silsesquioxane hybrid thermo-responsive FK506 hydrogel in a murine model of dry eye. Bioact Mater 9:77–91.
   PubMed Web of Science ®Google Scholar
• Herrera-Gómez F, Vásquez-Seoane M, Aguila WD, et al. (2017). Peripheral blood regulatory T cell counts as a predictive biomarker for the outcome of kidney transplant: a systematic review. Med Clin (Barc) 149:523–35.
   PubMed Web of Science ®Google Scholar
• Huijts CM, Santegoets SJ, De Jong TD, et al. (2017). Immunological effects of everolimus in patients with metastatic renal cell cancer. Int J Immunopathol Pharmacol 30:341–52.
   PubMed Web of Science ®Google Scholar
• Huynh NT, Passirani C, Saulnier P, et al. (2009). Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 379:201–9.
   PubMed Web of Science ®Google Scholar
• Jóhannsdóttir S, Jansook P, Stefánsson E, et al. (2015). Development of a cyclodextrin-based aqueous cyclosporin A eye drop formulations. Int J Pharm 493:86–95.
   PubMed Web of Science ®Google Scholar
• Jóhannsdóttir S, Kristinsson JK, Fülöp Z, et al. (2017). Formulations and toxicologic in vivo studies of aqueous cyclosporin A eye drops with cyclodextrin nanoparticles. Int J Pharm 529:486–90.
   PubMedGoogle Scholar
• Jabs DA. (2018). Immunosuppression for the uveitides. Ophthalmology 125:193–202.
   PubMed Web of Science ®Google Scholar
• Jayatilleke A. (2022). Immunosuppression in rheumatologic and auto-immune disease. Handb Exp Pharmacol 272:181–208.
   PubMedGoogle Scholar
• Jones L, Downie LE, Korb D, et al. (2017). TFOS DEWS II management and therapy report. Ocul Surf 15:575–628.
   PubMed Web of Science ®Google Scholar
• Kang CB, Hong Y, Dhe-Paganon S, et al. (2008). FKBP family proteins: immunophilins with versatile biological functions. Neurosignals 16:318–25.
   PubMed Web of Science ®Google Scholar
• Karn PR, Kim HD, Kang H, et al. (2014). Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion. Int J Nanomedicine 9:3791–800.
   PubMed Web of Science ®Google Scholar
• Kasper M, Gabriel D, Möller M, et al. (2018). Novel everolimus-loaded nanocarriers for topical treatment of murine experimental autoimmune uveoretinitis (EAU.). Exp Eye Res 168:49–56.
   PubMed Web of Science ®Google Scholar
• Kwon GS. (2003). Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst 20:357–403.
   PubMed Web of Science ®Google Scholar
• Laish I, Braun M, Mor E, et al. (2011). Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 17:15–22.
   PubMed Web of Science ®Google Scholar
• Li J, Du Y, Yang J, et al. (2005). Preparation and characterisation of low molecular weight chitosan and chito-oligomers by a commercial enzyme. Polymer Degrad Stability 87:441–8.
   Web of Science ®Google Scholar
• Li J, Wang X, Xie Y, et al. (2018). The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton’s tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma. Int J Cancer 142:202–13.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang Y, Han S, et al. (2011). Penetration enhancement of lidocaine hydrochlorid by a novel chitosan coated elastic liposome for transdermal drug delivery. J Biomed Nanotechnol 7:704–13.
   PubMed Web of Science ®Google Scholar
• Li N, Zhuang CY, Wang M, et al. (2012). Low molecular weight chitosan-coated liposomes for ocular drug delivery: in vitro and in vivo studies. Drug Deliv 19:28–35.
   PubMed Web of Science ®Google Scholar
• Li X, Nie SF, Kong J, et al. (2008). A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 363:177–82.
   PubMed Web of Science ®Google Scholar
• Linares-Alba MA, Gómez-Guajardo MB, Fonzar JF, et al. (2016). Preformulation studies of a liposomal formulation containing sirolimus for the treatment of dry eye disease. J Ocul Pharmacol Ther 32:11–22.
   PubMed Web of Science ®Google Scholar
• Liu S, Dozois MD, Chang CN, et al. (2016). Prolonged ocular retention of mucoadhesive nanoparticle eye drop formulation enables treatment of eye diseases using significantly reduced dosage. Mol Pharm 13:2897–905.
   PubMed Web of Science ®Google Scholar
• Loftsson T, BjöRnsdóttir S, Pálsdóttir G, et al. (1989). The effects of 2-hydroxypropyl-β-cyclodextrin on the solubility and stability of chlorambucil and melphalan in aqueous solution. Int J Pharm 57:63–72.
   Google Scholar
• Luaces-Rodríguez A, Touriño-Peralba R, Alonso-Rodríguez I, et al. (2018). Preclinical characterization and clinical evaluation of tacrolimus eye drops. Eur J Pharm Sci 120:152–61.
   PubMed Web of Science ®Google Scholar
• Lucey MR, Terrault N, Ojo L, et al. (2013). Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 19:3–26.
   PubMed Web of Science ®Google Scholar
• Macdonald A, Scarola J, Burke JT, et al. (2000). Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 22 Suppl B:B101–121.
   PubMed Web of Science ®Google Scholar
• Madni A, Rahem MA, Tahir N, et al. (2017). Non-invasive strategies for targeting the posterior segment of eye. Int J Pharm 530:326–45.
   PubMed Web of Science ®Google Scholar
• Mahmoudi A, Malaekeh-Nikouei B, Hanafi-Bojd MY, et al. (2020). Preliminary in vivo safety evaluation of a tacrolimus eye drop formulation using hydroxypropyl beta cyclodextrin after ocular administration in NZW rabbits. Clin Ophthalmol 14:947–53.
   PubMed Web of Science ®Google Scholar
• Mccoy M. (2015). Allergan Licenses Dry Eye Treatment. Chemical and engineering news: “news edition” of the American Chemical Society 93:17.
   Google Scholar
• Mehra N, Aqil M, Sultana Y. (2021). A grafted copolymer-based nanomicelles for topical ocular delivery of everolimus: Formulation, characterization, ex-vivo permeation, in-vitro ocular toxicity, and stability study. Eur J Pharm Sci 159:105735.
   PubMed Web of Science ®Google Scholar
• Modi D, Nirmal J, Warsi MH, et al. (2022). Formulation and development of tacrolimus-gellan gum nanoformulation for treatment of dry eye disease. Colloids Surf B Biointerfaces 211:112255.
   PubMed Web of Science ®Google Scholar
• Murphy CJ, Bentley E, Miller PE, et al. (2011). The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs. Invest Ophthalmol Vis Sci 52:3174–80.
   PubMed Web of Science ®Google Scholar
• Nakagawa N, Ishiyama K, Tanabe M, et al. (2021). The effectiveness of immunosuppressive therapy in patients with aplastic anaemia secondary to chemoradiotherapy for cancers. Br J Haematol 195:770–80.
   PubMed Web of Science ®Google Scholar
• Nakowitsch S, Kaintz C, Graf P, et al. (2016). Increased uptake of lipophilic immunosuppressive compounds in cornea and retina based on solubilization in an aqueous formulation. Invest Ophthalmol Visual Sci 57:275.
   Web of Science ®Google Scholar
• Nankivell BJ, Borrows RJ, Fung CL, et al. (2003). The natural history of chronic allograft nephropathy. N Engl J Med 349:2326–33.
   PubMedGoogle Scholar
• Nguyen LS, Vautier M, Allenbach Y, et al. (2019). Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation. Drug Saf 42:813–25.
   PubMed Web of Science ®Google Scholar
• Niu M, Lu Y, Hovgaard L, et al. (2011). Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomedicine 6:1155–66.
   PubMed Web of Science ®Google Scholar
• Nikoofal-Sahlabadi S, Mohajeri SA, Banaee T, et al. (2013). Evaluation of cyclosporine A eye penetration after administration of liposomal or conventional forms in animal model. Nanomed J 1:48–54.
   Google Scholar
• Paghdal KV, Schwartz RA. (2007). Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol 57:1046–50.
   PubMed Web of Science ®Google Scholar
• Palestine AG, Nussenblatt RB, Chan CC. (1984). Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med 77:652–6.
   PubMed Web of Science ®Google Scholar
• Panahi FH, Peighambardoust SJ, Davaran S. (2017). Development and characterization of PLA-mP EG copolymer containing iron nanoparticle-coated carbon nanotubes for controlled delivery of Docetaxel. 117:117–131.
   Google Scholar
• Pehlivan SB, Yavuz B, alamak S, et al. (2015). Preparation and in vitro/in vivo evaluation of cyclosporin A-loaded nanodecorated ocular implants for subconjunctival application. J Pharm Sci 104:1709–20.
   PubMed Web of Science ®Google Scholar
• Perez VL, Caicedo A, Berman DM, et al. (2011). The anterior chamber of the eye as a clinical transplantation site for the treatment of diabetes: a study in a baboon model of diabetes. Diabetologia 54:1121–6.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, De Paiva CS. (2017). The pathophysiology of dry eye disease: What we know and future directions for research. Ophthalmology 124:S4–S13.
   PubMed Web of Science ®Google Scholar
• Phan QT, Le MH, Le TT, et al. (2016). Characteristics and cytotoxicity of folate-modified curcumin-loaded PLA-PEG micellar nano systems with various PLA:PEG ratios. Int J Pharm 507:32–40.
   PubMed Web of Science ®Google Scholar
• Rollan MP, Cabrera R, Schwartz RA. (2022). Current knowledge of immunosuppression as a risk factor for skin cancer development. Crit Rev Oncol Hematol 177:103754.
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Dilnawaz F, Krishnakumar S. (2008). Nanotechnology in ocular drug delivery. Drug Discov Today 13:144–51.
   PubMed Web of Science ®Google Scholar
• Sankar V, Ruckmani K, Durga S, et al. (2010). Proniosomes as drug carriers. Pak J Pharm Sci 23:103–7.
   PubMed Web of Science ®Google Scholar
• Schtzlein AG. (2021). Polymeric micelles for the enhanced deposition of hydrophobic drugs into ocular tissues, without plasma exposure. Pharmaceutics 13:744.
   PubMed Web of Science ®Google Scholar
• Shah M, Edman MC, Janga SR, et al. (2013). A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren’s syndrome. J Control Release 171:269–79.
   PubMed Web of Science ®Google Scholar
• Shapiro R, Fung JJ, Jain AB, et al. (1990). The side effects of FK 506 in humans. Transplant Proc 22:35–6.
   PubMed Web of Science ®Google Scholar
• Shen J, Deng Y, Jin X, et al. (2010). Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution. Int J Pharm 402:248–53.
   PubMed Web of Science ®Google Scholar
• Shi B, Zhao M, Geng T, et al. (2017). Effectiveness and safety of immunosuppressive therapy in neuromyelitis optica spectrum disorder during pregnancy. J Neurol Sci 377:72–6.
   PubMed Web of Science ®Google Scholar
• Shimpi S, Chauhan B, Shimpi P. (2005). Cyclodextrins: application in different routes of drug administration. Acta Pharm 55:139–56.
   PubMedGoogle Scholar
• Siegl C, König-Schuster M, Nakowitsch S, et al. (2019). Pharmacokinetics of topically applied tacrolimus dissolved in Marinosolv, a novel aqueous eye drop formulation. Eur J Pharm Biopharm 134:88–95.
   PubMed Web of Science ®Google Scholar
• Simamora P, Alvarez JM, Yalkowsky SH. (2001). Solubilization of rapamycin. Int J Pharm 213:25–9.
   PubMed Web of Science ®Google Scholar
• Tang Z, Wang L, Xia Z, et al. (2019). HPLC-MS/MS-based analysis of everolimus in rabbit aqueous humor: pharmacokinetics of in situ gel eye drops of suspension. Bioanalysis 11:267–78.
   PubMed Web of Science ®Google Scholar
• Tang Z, Yin L, Zhang Y, et al. (2019). Preparation and study of two kinds of ophthalmic nano-preparations of everolimus. Drug Deliv 26:1235–42.
   PubMed Web of Science ®Google Scholar
• Thomson AW, Turnquist HR, Raimondi G. (2009). Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9:324–37.
   PubMed Web of Science ®Google Scholar
• Utine CA, Stern M, Akpek EK. (2010). Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm 18:352–61.
   PubMed Web of Science ®Google Scholar
• Vichyanond P, Kosrirukvongs P. (2013). Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis. Curr Allergy Asthma Rep 13:308–14.
   PubMed Web of Science ®Google Scholar
• Wang L, Tang Z, Shi M, et al. (2019). Pharmacokinetic study of sirolimus ophthalmic formulations by consecutive sampling and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 164:337–44.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang M, Liu Y, et al. (2019). Effect of rapamycin microspheres in Sjögren syndrome dry eye: preparation and outcomes. Ocul Immunol Inflamm 27:1357–64.
   PubMed Web of Science ®Google Scholar
• Wang T, He X, Ran N, et al. (2021). Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia. J Clin Lab Anal 35:e23922.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang S, Zhang Y. (2016). Advance of the application of nano-controlled release system in ophthalmic drug delivery. Drug Deliv 23:2897–901.
   PubMed Web of Science ®Google Scholar
• Wirta DL, Torkildsen GL, Moreira HR, et al. (2019). A clinical phase II study to assess efficacy, safety, and tolerability of waterfree ­cyclosporine formulation for treatment of dry eye disease. Ophthalmology 126:792–800.
   PubMed Web of Science ®Google Scholar
• Wojciechowski D, Wiseman A. (2021). Long-term immunosuppression management: opportunities and uncertainties. Clin J Am Soc Nephrol 16:1264–71.
   PubMed Web of Science ®Google Scholar
• Yatscoff RW, Wang P, Chan K, et al. (1995). Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 17:666–71.
   PubMed Web of Science ®Google Scholar
• Yavuz B, Bozdağ Pehlivan S, Kaffashi A, et al. (2016). In vivo tissue distribution and efficacy studies for cyclosporin A loaded nano-decorated subconjunctival implants. Drug Deliv 23:3279–84.
   PubMed Web of Science ®Google Scholar
• Yu Y, Chen D, Li Y, et al. (2018). Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies. Drug Deliv 25:888–99.
   PubMed Web of Science ®Google Scholar
• Zahir-Jouzdani F, Khonsari F, Soleimani M, et al. (2019). Nanostructured lipid carriers containing rapamycin for prevention of corneal fibroblasts proliferation and haze propagation after burn injuries: In vitro and in vivo. J Cell Physiol 234:4702–12.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zheng Y, Li M, et al. (2020). Carboxymethyl cellulose-coated tacrolimus nonspherical microcrystals for improved therapeutic efficacy of dry eye. Macromol Biosci 20:e2000079.
   PubMed Web of Science ®Google Scholar
• Zheng J, Ying C, Dong S, et al. (2012). In vitro release and irritation of ocular sirolimus chitosan-coated liposomal in-situ gels. China Pharmacist 15:609–12.
   Google Scholar